Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1528-3658

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome ; volume:27 ; number:1 ; day:11 ; month:5 ; year:2021 ; pages:1-13 ; date:12.2021
Molecular medicine ; 27, Heft 1 (11.5.2021), 1-13, 12.2021

Creator: Palmblad, Karin
Schierbeck, Hanna
Sundberg, Erik
Horne, Anna-Carin
Erlandsson Harris, Helena
Henter, Jan-Inge
Andersson, Ulf

Contributor: SpringerLink (Online service)

DOI: 10.1186/s10020-021-00308-0

URN: urn:nbn:de:101:1-2021091207074322044783

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:28 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Palmblad, Karin
Schierbeck, Hanna
Sundberg, Erik
Horne, Anna-Carin
Erlandsson Harris, Helena
Henter, Jan-Inge
Andersson, Ulf
SpringerLink (Online service)

Other Objects (12)

HMGB1 mediates lipopolysaccharide-induced macrophage autophagy and pyroptosis

Retraction Note to: High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome

Cytokine active disulfide-HMGB1 increased during severe macrophage activation syndrome

NK cell HMGB1 mediates IL-2-induced “systemic autophagic” toxicity

Molecular mechanisms of etoposide

Downregulation of HMGB1 carried by macrophage-derived extracellular vesicles delays atherosclerotic plaque formation through Caspase-11-dependent macrophage pyroptosis

High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus

Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis

Systemic immune profile in Prader-Willi syndrome: elevated matrix metalloproteinase and myeloperoxidase and reduced macrophage inhibitory factor

Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome

Alarmin HMGB1 induces systemic and brain inflammatory exacerbation in post-stroke infection rat model

Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations

HMGB1 mediates lipopolysaccharide-induced macrophage autophagy and pyroptosis

Retraction Note to: High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome

Cytokine active disulfide-HMGB1 increased during severe macrophage activation syndrome

NK cell HMGB1 mediates IL-2-induced “systemic autophagic” toxicity

Molecular mechanisms of etoposide

Downregulation of HMGB1 carried by macrophage-derived extracellular vesicles delays atherosclerotic plaque formation through Caspase-11-dependent macrophage pyroptosis

High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus

Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis

Systemic immune profile in Prader-Willi syndrome: elevated matrix metalloproteinase and myeloperoxidase and reduced macrophage inhibitory factor

Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome

Alarmin HMGB1 induces systemic and brain inflammatory exacerbation in post-stroke infection rat model

Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations

HMGB1 mediates lipopolysaccharide-induced macrophage autophagy and pyroptosis

Retraction Note to: High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome

Cytokine active disulfide-HMGB1 increased during severe macrophage activation syndrome

NK cell HMGB1 mediates IL-2-induced “systemic autophagic” toxicity

Molecular mechanisms of etoposide

Downregulation of HMGB1 carried by macrophage-derived extracellular vesicles delays atherosclerotic plaque formation through Caspase-11-dependent macrophage pyroptosis

High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus

Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis

Systemic immune profile in Prader-Willi syndrome: elevated matrix metalloproteinase and myeloperoxidase and reduced macrophage inhibitory factor

Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome

Alarmin HMGB1 induces systemic and brain inflammatory exacerbation in post-stroke infection rat model

Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

HMGB1 mediates lipopolysaccharide-induced macrophage autophagy and pyroptosis

Retraction Note to: High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome

Cytokine active disulfide-HMGB1 increased during severe macrophage activation syndrome

NK cell HMGB1 mediates IL-2-induced “systemic autophagic” toxicity

Molecular mechanisms of etoposide

Downregulation of HMGB1 carried by macrophage-derived extracellular vesicles delays atherosclerotic plaque formation through Caspase-11-dependent macrophage pyroptosis

High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus

Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis

Systemic immune profile in Prader-Willi syndrome: elevated matrix metalloproteinase and myeloperoxidase and reduced macrophage inhibitory factor

Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome

Alarmin HMGB1 induces systemic and brain inflammatory exacerbation in post-stroke infection rat model

Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations

HMGB1 mediates lipopolysaccharide-induced macrophage autophagy and pyroptosis

Retraction Note to: High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome

Cytokine active disulfide-HMGB1 increased during severe macrophage activation syndrome

NK cell HMGB1 mediates IL-2-induced “systemic autophagic” toxicity

Molecular mechanisms of etoposide

Downregulation of HMGB1 carried by macrophage-derived extracellular vesicles delays atherosclerotic plaque formation through Caspase-11-dependent macrophage pyroptosis

High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus

Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis

Systemic immune profile in Prader-Willi syndrome: elevated matrix metalloproteinase and myeloperoxidase and reduced macrophage inhibitory factor

Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome

Alarmin HMGB1 induces systemic and brain inflammatory exacerbation in post-stroke infection rat model

Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations

HMGB1 mediates lipopolysaccharide-induced macrophage autophagy and pyroptosis

Retraction Note to: High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome

Cytokine active disulfide-HMGB1 increased during severe macrophage activation syndrome

NK cell HMGB1 mediates IL-2-induced “systemic autophagic” toxicity

Molecular mechanisms of etoposide

Downregulation of HMGB1 carried by macrophage-derived extracellular vesicles delays atherosclerotic plaque formation through Caspase-11-dependent macrophage pyroptosis

High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus

Increased serum calpain activity is associated with HMGB1 levels in systemic sclerosis

Systemic immune profile in Prader-Willi syndrome: elevated matrix metalloproteinase and myeloperoxidase and reduced macrophage inhibitory factor

Association of HMGB1 polymorphisms with outcome in patients with systemic inflammatory response syndrome

Alarmin HMGB1 induces systemic and brain inflammatory exacerbation in post-stroke infection rat model

Urine levels of HMGB1 in Systemic Lupus Erythematosus patients with and without renal manifestations

Related objects

Reset password